Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations

por Paik, Paul K., Pfeiffer, Boris M., Vioix, Helene, Garcia, Andrea, Postma, Maarten J.
Publicado 2022

Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14...

por Yang, Mo, Vioix, Helene, Sachdev, Rameet, Stargardter, Matthew, Tosh, Jon, Pfeiffer, Boris M., Paik, Paul K.
Publicado 2023

Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer

por Luo, Leo Y., Samstein, Robert M., Dick-Godfrey, Rosalind, Sidiqi, Baho, Wang, Chunyu, Oro, Federica, Sonnick, Mark, Paik, Paul K., Chaft, Jamie E., Shaverdian, Narek, Gomez, Daniel R., Rimner, Andreas, Wu, Abraham J.
Publicado 2020

Real-world insights into patients with advanced NSCLC and MET alterations

por Bittoni, Marisa, Yang, James Chih-Hsin, Shih, Jin-Yuan, Peled, Nir, Smit, Egbert F., Camidge, D. Ross, Arasada, Rajeswara Rao, Oksen, Dina, Boutmy, Emmanuelle, Stroh, Christopher, Johne, Andreas, Carbone, David P., Paik, Paul K.
Publicado 2021

Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas

por Paik, Paul K., Luo, Jia, Ai, Ni, Kim, Rachel, Ahn, Linda, Biswas, Anup, Coker, Courtney, Ma, Wanchao, Wong, Phillip, Buonocore, Darren J., Lai, W. Victoria, Chaft, Jamie E., Acharyya, Swarnali, Massagué, Joan, Kris, Mark G.
Publicado 2022

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study

por Sakai, Hiroshi, Morise, Masahiro, Kato, Terufumi, Matsumoto, Shingo, Sakamoto, Tomohiro, Kumagai, Toru, Tokito, Takaaki, Atagi, Shinji, Kozuki, Toshiyuki, Tanaka, Hiroshi, Chikamori, Kenichi, Shinagawa, Naofumi, Takeoka, Hiroaki, Bruns, Rolf, Straub, Josef, Schumacher, Karl Maria, Paik, Paul K
Publicado 2021

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management

por Veillon, Remi, Sakai, Hiroshi, Le, Xiuning, Felip, Enriqueta, Cortot, Alexis B., Smit, Egbert F., Park, Keunchil, Griesinger, Frank, Britschgi, Christian, Wu, Yi-Long, Melosky, Barbara, Baijal, Shobhit, de Castro, Gilberto, Sedova, Michaela, Berghoff, Karin, Otto, Gordon, Paik, Paul K.
Publicado 2022

Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial

por Mazieres, Julien, Paik, Paul K., Garassino, Marina C., Le, Xiuning, Sakai, Hiroshi, Veillon, Remi, Smit, Egbert F., Cortot, Alexis B., Raskin, Jo, Viteri, Santiago, Wu, Yi-Long, Yang, James C. H., Ahn, Myung-Ju, Ma, Rui, Zhao, Jun, O’Brate, Aurora, Berghoff, Karin, Bruns, Rolf, Otto, Gordon, Johne, Andreas, Felip, Enriqueta, Thomas, Michael
Publicado 2023

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

por Fan, Pang-Dian, Narzisi, Giuseppe, Jayaprakash, Anitha D., Venturini, Elisa, Robine, Nicolas, Smibert, Peter, Germer, Soren, Yu, Helena A., Jordan, Emmet J., Paik, Paul K., Janjigian, Yelena Y., Chaft, Jamie E., Wang, Lu, Jungbluth, Achim A., Middha, Sumit, Spraggon, Lee, Qiao, Huan, Lovly, Christine M., Kris, Mark G., Riely, Gregory J., Politi, Katerina, Varmus, Harold, Ladanyi, Marc
Publicado 2018

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration

por Drilon, Alexander, Clark, Jeffrey W., Weiss, Jared, Ou, Sai-Hong Ignatius, Camidge, D. Ross, Solomon, Benjamin J., Otterson, Gregory A., Villaruz, Liza C., Riely, Gregory J., Heist, Rebecca S., Awad, Mark M., Shapiro, Geoffrey I., Satouchi, Miyako, Hida, Toyoaki, Hayashi, Hidetoshi, Murphy, Danielle A., Wang, Sherry C., Li, Sherry, Usari, Tiziana, Wilner, Keith D., Paik, Paul K.
Publicado 2020

Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer

por Biswas, Anup Kumar, Han, Seoyoung, Tai, Yifan, Ma, Wanchao, Coker, Courtney, Quinn, S. Aidan, Shakri, Ahmad Rushdi, Zhong, Timothy James, Scholze, Hanna, Lagos, Galina G., Mela, Angeliki, Manova-Todorova, Katia, de Stanchina, Elisa, Ferrando, Adolfo A., Mendelsohn, Cathy, Canoll, Peter, Yu, Helena A., Paik, Paul K., Saqi, Anjali, Shu, Catherine A., Kris, Mark G., Massague, Joan, Acharyya, Swarnali
Publicado 2022

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

por Le, Xiuning, Paz-Ares, Luis G., Van Meerbeeck, Jan, Viteri, Santiago, Galvez, Carlos Cabrera, Smit, Egbert F., Garassino, Marina, Veillon, Remi, Baz, David Vicente, Pradera, Jose Fuentes, Sereno, María, Kozuki, Toshiyuki, Kim, Young-Chul, Yoo, Seung Soo, Han, Ji-Youn, Kang, Jin-Hyoung, Son, Choon-Hee, Choi, Yoon Ji, Stroh, Christopher, Juraeva, Dilafruz, Vioix, Helene, Bruns, Rolf, Otto, Gordon, Johne, Andreas, Paik, Paul K.
Publicado 2023

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

por Le, Xiuning, Sakai, Hiroshi, Felip, Enriqueta, Veillon, Remi, Garassino, Marina Chiara, Raskin, Jo, Cortot, Alexis B., Viteri, Santiago, Mazieres, Julien, Smit, Egbert F., Thomas, Michael, Iams, Wade T., Cho, Byoung Chul, Kim, Hye Ryun, Yang, James Chih-Hsin, Chen, Yuh-Min, Patel, Jyoti D., Bestvina, Christine M., Park, Keunchil, Griesinger, Frank, Johnson, Melissa, Gottfried, Maya, Britschgi, Christian, Heymach, John, Sikoglu, Elif, Berghoff, Karin, Schumacher, Karl-Maria, Bruns, Rolf, Otto, Gordon, Paik, Paul K.
Publicado 2022

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

por Valero, Cristina, Lee, Mark, Hoen, Douglas, Weiss, Kate, Kelly, Daniel W., Adusumilli, Prasad S., Paik, Paul K., Plitas, George, Ladanyi, Marc, Postow, Michael A., Ariyan, Charlotte E., Shoushtari, Alexander N., Balachandran, Vinod P., Hakimi, A. Ari, Crago, Aimee M., Long Roche, Kara C., Smith, J. Joshua, Ganly, Ian, Wong, Richard J., Patel, Snehal G., Shah, Jatin P., Lee, Nancy Y., Riaz, Nadeem, Wang, Jingming, Zehir, Ahmet, Berger, Michael F., Chan, Timothy A., Seshan, Venkatraman E., Morris, Luc G. T.
Publicado 2021

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

por Lovly, Christine M., McDonald, Nerina T., Chen, Heidi, Ortiz-Cuaran, Sandra, Heukamp, Lukas C., Yan, Yingjun, Florin, Alexandra, Ozretić, Luka, Lim, Diana, Wang, Lu, Chen, Zhao, Chen, Xi, Lu, Pengcheng, Paik, Paul K., Shen, Ronglai, Jin, Hailing, Buettner, Reinhard, Ansén, Sascha, Perner, Sven, Brockmann, Michael, Bos, Marc, Wolf, Jürgen, Gardizi, Masyar, Wright, Gavin M., Solomon, Benjamin, Russell, Prudence A., Rogers, Toni-Maree, Suehara, Yoshiyuki, Red-Brewer, Monica, Tieu, Rudy, de Stanchina, Elisa, Wang, Qingguo, Zhao, Zhongming, Johnson, David H., Horn, Leora, Wong, Kwok-Kin, Thomas, Roman K., Ladanyi, Marc, Pao, William
Publicado 2014